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Abstract
Objectives To estimate productivity loss and associated
indirect costs in high-risk patients treated for hyperlipi-
demia who experience cardiovascular (CV) events.
Methods Retrospective population-based cohort study
conducted using Swedish medical records linked to
national registers. Patients were included based on pre-
scriptions of lipid-lowering therapy between 1 January
2006 and 31 December 2011 and followed until 31
December 2012 for identification of CV events and esti-
mation of work productivity loss (sick leave and disability
pension) and indirect costs. Patients were stratified into two
cohorts based on CV risk level: history of major cardio-
vascular disease (CVD) and coronary heart disease (CHD)
risk equivalent. Propensity score matching was applied to
compare patients with new events (cases) to patients
without new events (controls). The incremental effect of
CV events was estimated using a difference-in-differences
design, comparing productivity loss among cases and
controls during the year before and the year after the cases’
event.
Results The incremental effect on indirect costs was lar-
gest in the CHD risk equivalent cohort (n = 2946) at
€3119 (P value\0.01). The corresponding figure in the
major CVD history cohort (n = 4508) was €2210 (P value
\0.01). There was substantial variation in productivity loss
depending on the type of event. Transient ischemic attack
and revascularization had no significant effect on indirect
costs. Myocardial infarction (€3465), unstable angina
(€2733) and, most notably, ischemic stroke (€6784) yielded
substantial incremental cost estimates (P values\0.01).
Conclusions Indirect costs related to work productivity
losses of CV events are substantial in Swedish high-risk
patients treated for hyperlipidemia and vary considerably
by type of event.
Keywords Cardiovascular disease  Hyperlipidemia 
Indirect costs  Productivity
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Introduction
Cardiovascular disease (CVD), with the usual underlying
pathology of atherosclerosis, is a major cause of premature
death worldwide, and a substantial source of disability [1].
The most common manifestation of CVD is coronary heart
disease (CHD). CHD has been estimated to be the leading
cause of disability in Europe, accounting for approximately
10 % of total disability-adjusted life years [2]. CHD has
also been estimated to be the leading cause of premature
permanent disability in the US labor force [1]. Conse-
quently, CHD and other forms of CVD contribute
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extensively to the total cost of healthcare [3–6]. Although
CVD is most prevalent among the older population, a
substantial number of working-age patients are diagnosed
[7]. Indirect costs due to lost productivity therefore account
for an important part of the total costs of CVD [1]. In
Europe, indirect costs associated with productivity losses
have been found to correspond to 21 % of the total costs of
CVD [8]. The American Heart Association have estimated
that indirect costs accounted for 36 % of the total 1-year
costs of CVD in the US in 2006 [9], and that CVD-related
indirect costs were US $172 billion in 2010 [10].
While several studies have reported the large societal
costs associated with CVD, there is a scarcity of studies
that have focused specifically on costs related to new car-
diovascular (CV) events. This is especially the case for
indirect costs. The few available studies that have esti-
mated indirect costs related to productivity losses due to
CV events are either relatively old [11], have been limited
by sample size [12], or have focused on the effect of
specific medical interventions on productivity losses [13,
14]. In addition, many estimates have been based on
questionnaires that are vulnerable to recall bias and often
yield varied estimates of productivity losses even when
administered in the same setting [6]. Furthermore, com-
prehensive estimates of indirect costs of CV events across
the CV risk continuum of hyperlipidemia patients are
lacking from the literature. Recent studies have started to
address these issues, however [15].
The objective of this study was to estimate productivity
loss and indirect costs associatedwith CV events in high-risk
hyperlipidemia patients in Sweden. Productivity losses were
estimated by CV risk level and by the following event types:
myocardial infarction (MI), ischemic stroke (IS), revascu-
larization, unstable angina pectoris (UA), heart failure (HF),
and transient ischemic attack (TIA). By providing estimates
of indirect costs associated with lost productivity due to CV
events, stratified by risk level and by CV event type, this
study fills important gaps in available evidence. Reliable and
up-to-date estimates of costs of clinical events are essential
in economic evaluation studies comparing standard care to
novel health technologies and interventions aimed at low-
ering the incidence of these events.
Methods
Study design and population
This was a retrospective population-based cohort register
study based on a matched control design, conducted using
patient-level data. The primary data sources for the study
were electronic medical records in Swedish primary care,
three national compulsory health registers governed by the
National Board of Health and Welfare, and the Swedish
Social Insurance Register. Unique individual patient ID
numbers were available for all data sources, allowing for
linkage of individual patients between data sets. The
linkage of de-identified individual patients was performed
by the National Board of Health and Welfare. The study
was approved by the Swedish Ethics Review Board.
The study population was defined as high-risk patients
with hyperlipidemia, as elevation of low-density lipoprotein
cholesterol levels is closely linked to the development of
CHD [1]. Patients were identified for inclusion in the study
population based on treatment with lipid-lowering therapy
(LLT), as registered in the Prescribed Drug Register. This
was deemed the most accurate way of identifying hyper-
lipidemia patients in Sweden as the diagnosis of hyper-
lipidemia is often made in primary care, where reporting
and coding of diagnoses is not mandatory and therefore
relatively poor. High-risk patients with a filled prescription
of LLT during the period between 1 January 2006 and 31
December 2011 were included, if a second filled prescrip-
tion followed within 6 months. The study inclusion date
was defined as the date of the first of the filled prescriptions
for LLT. High risk was defined as a history of major CVD or
diagnosis of a CHD risk equivalent condition, based on
patient diagnosis history from 10 years prior to and up until
study inclusion. Patients who were not defined as high risk
were excluded from the study population.
Patients with a history of major CVD and patients with a
CHD risk equivalent condition were considered as separate
cohorts, in order to quantify productivity loss across the
continuum of high-risk hyperlipidemia patients. The two
cohorts were considered together in the analysis of specific
event types, however, due to sample size considerations.
The cohorts were defined based on the National Choles-
terol Education Program Adult Treatment Panel III
guidelines [16] and the European Society of Cardiology
guidelines [17]. The two cohorts were defined as follows:
1. History of major CVD cohort: prior revascularization
or diagnosis of MI, UA, or ischemic stroke.
2. CHD risk equivalent cohort: patients not included in
the history of major CVD cohort and with prior
diagnosis of diabetes, peripheral artery disease,
abdominal aortic aneurysm, TIA, or stable angina
pectoris.
Patients of working age at time of study inclusion were
observed from study inclusion until 31 December 2011
(exposure time) for identification of new CV events using
the National Patient Register. Working age was defined as
between 20 and 64 years of age. The date of the first new
CV event following study inclusion was defined as the
index date. A new event was defined as an inpatient pri-
mary diagnosis of acute MI, UA, ischemic stroke, HF, TIA,
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or any inpatient or outpatient procedure code indicating
revascularization. Revascularization was defined as per-
cutaneous transluminal coronary angioplasty (PTCA). A
minimum of 60 days was required between events of the
same type in order for them to be considered separate
events. In addition, a minimum of 60 days was required
between any event type and a revascularization in order for
the revascularization to count as a separate event. Patients
were followed for 1 year after the index date for estimation
of productivity loss and associated costs.
Productivity loss was defined as the sum of net sick
leave and net disability pension days, both of which are
part of the Swedish social insurance system. All people
who live or work in Sweden are automatically covered by
the Swedish social insurance, which provides financial
protection for families and children. Individual-level
statistics are available in the Social Insurance Register on
all sick leave episodes lasting longer than 14 days (start
and end dates of all episodes and cause of sick leave) that
are covered by the social insurance at an individual level.
Short-term sick leave episodes (B14 days) are the
responsibility of the employer and are thus not captured in
the register or in this study. Moreover, individual data are
available on episodes of disability pension (‘‘sickness
compensation’’ for 30- to 64-year-olds and ‘‘activity
compensation’’ for 19- to 29-year-olds). Disability pension
may be either time-limited or permanent, and requires at
least an estimated 25 % reduction in work ability that is
expected to remain for at least 1 year. The National Social
Insurance Agency is the sole administrator of sick leave
and long-term disability in Sweden. The study design thus
allowed for complete coverage of productivity loss in the
selected sample population of the study (with the exception
of sick leave episodes B14 days). Net days were used as
sick leave and disability pension may be either complete or
partial in Sweden. Net days for each sick leave and dis-
ability pension episode were calculated by multiplying the
number of days by the level of compensation of the
respective episode. Thus, 30 days of 50 % sick leave
would thus result in a net 15 days of sick leave, for
example. Weekends and holidays were included in calcu-
lations of sick leave and disability pension days, meaning
that the maximum number of days lost was 365 per year.
The value of lost productivity was estimated using the
human capital approach [18]. The human capital approach
assumes that the cost of a person’s reduced productivity is
equal to the amount an employer would be willing to pay
for that production [18]. This was assumed to be the
average gross salary plus employer contributions in Swe-
den. The average monthly pay was taken from the database
of Statistics Sweden and was 27,600 SEK for women and
32,100 SEK for men in 2012 [19]. Employer contributions
in Sweden are 31.42 % [20]. The average daily salary plus
employer contributions was thus calculated to be 1192
SEK for women and 1386 SEK for men. Note that these
figures include weekends and holidays, ensuring that
indirect costs were not overestimated by including week-
ends and holidays in the calculations of sick leave and
disability pension days. The difference in wages of men
and women was taken into account when calculating
indirect costs by adjusting for the gender distribution of
patients. All costs were inflated to 2014 SEK using publicly
available inflation data and converted to 2014 EUR (con-
version rate: 1 EUR = 9.27 SEK).
Statistical analysis
Patients without a new CV event between study inclusion
and 31 December 2011 (controls) were matched to patients
with a new CV event (cases) within the same CVD risk
cohort using propensity score matching based on a 1:1
match without replacement. The covariates used in the
matching were measured at time of study inclusion. Con-
trols were then assigned the same index date as that of their
matched cases. The matching covariates were: age; gender;
Charlson comorbidity index based on diagnoses during the
5-year period prior to study inclusion; number of hospital
visits related to CV events during the 1-year period prior to
study inclusion; and days of hospitalization related to CV
events during the 1-year period prior to study inclusion. In
addition, a case was matched to a control only if their study
inclusion date occurred during the same calendar year. The
propensity score was estimated using logistic regression
and the caliper approach was used for matching. The
caliper method uses a tolerance level of the maximum
propensity score distance to avoid the risk of bad matches.
The maximum propensity score distance was set to one-
fourth of the standard deviation of the propensity score.
The quality of the matching was evaluated by investigating
the standardized differences between cases and matched
controls in the variables used in the matching. An ex-ante
limit of 10 % in standardized differences was set for all
variables used in the matching.
A difference-in-differences (DiD) approach was
employed to obtain estimates of productivity loss and
indirect costs associated with new CV events. Productivity
loss was calculated for each case and each corresponding
matched control during the 1-year period prior to index
event (pre period) and during the 1-year period following
index event (post period). The primary outcome was
defined as the difference in the post versus pre difference in
productivity loss between cases and propensity score
matched controls.
DiD estimate ¼ ð½Post periodCasePre periodCase
 ½Post periodControlPre periodControlÞ
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The DiD approach was used in order to control for
potential confounders and limit bias in the obtained esti-
mates. The within-subject comparison of cases before and
after the event controlled for all time-invariant unobserv-
able and observable characteristics by using each case as its
own control. Further, the within-subject comparison of
controls before and after index was used for correcting for
secular trends and shocks to the outcome variable that
would otherwise bias the pre versus post event comparison
of cases. Controlling for such temporal effects is crucial
when studying productivity losses in Sweden as changes
have been made to the social insurance system in recent
years [21], and sick leave and disability pension are likely
correlated with the business cycle. In addition, the match-
ing of cases and controls based on observable character-
istics was performed to ensure that secular trends and
shocks that affect productivity losses impact on cases and
controls equally, by constructing the control cohort to be
similar to cases in terms of observable characteristics.
Case patients were followed for 1 year following the
index event in parallel to their matched controls, and were
censored when either they or their matched control died,
whichever came first. In addition, matched patient pairs
were censored at time of a second event in cases following
index in order to ensure that the estimates of productivity
loss and costs of the index event were not influenced by
productivity losses and costs related to subsequent events.
Furthermore, patient pairs were removed from the analysis
if the control was no longer alive at index date.
The non-parametric Wilcoxon signed-ranked test was
used to test for statistical significance in differences in
costs. Differences were considered statistically significant
if P values were less than 0.05.
All data management and statistical analysis was per-
formed using MySQL and Stata 12.
Results
Patient attrition and characteristics
A total of 24,931 working age patients treated for
hyperlipidemia were identified for inclusion in the study
and stratified to one of the two cohorts. Of the included
patients, 10,755 (43 %) were stratified to the history of
major CVD cohort and the remaining 14,176 (57 %)
patients were stratified to the CHD risk equivalent cohort.
Of these, 2344 (22 %) and 1517 (11 %) patients, respec-
tively, experienced a new CV event following study
inclusion. Outcomes were assessed only in cases matched
to a control who was still alive at the index date. Out-
comes were thus assessed in 2254 cases and equally many
controls with a history of major CVD, and in 1473 CHD
risk equivalent cases and equally many CHD risk equiv-
alent controls. Figure 1 illustrates the stepwise inclusion
and exclusion of patients, by cohort, following this
procedure.
Standardized differences were lower than the ex-ante
limit of 10 % for all of the variables included in the
matching at study inclusion. The characteristics of the two
cohorts at index date are presented in Table 1. In both
cohorts, cases and controls were balanced at index date in
terms of age and gender. Cases were noticeably more
comorbid than controls in both cohorts, however, despite
the fact that the Charlson index was used in the matching of
patients at time of study inclusion. This indicates that the
prevalence of comorbid conditions increased more in cases
between time of study inclusion and index date than in
controls.
The two cohorts were similar in terms of age at index,
while a larger percentage of CHD risk equivalent patients
were female compared to patients with a history of major
CVD. The CHD risk equivalent patients were also more
comorbid compared to their history of major CVD
counterparts.
Paents with a new CV event whose matched control was sll alive at the 
index date (paents for whom outcomes were assessed)
Paents with history of major CVD
n = 2,254
CHD risk equivalent paents
n = 1,473
Paents with a new CV event who were matched to paents without 
 a new CV event
Paents with history of major CVD
n = 2,342
CHD risk equivalent paents
n = 1,509
Paents with a new CV event during exposure me
Paents with history of major CVD
n = 2,344
CHD risk equivalent paents
n = 1,517
Hyperlipidemia paents of working age
Paents with history of major CVD
n = 10,755
CHD risk equivalent paents
n = 14,176
Fig. 1 Patient attrition
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Productivity loss by risk level
Table 2 presents productivity losses in both cohorts. The
corresponding indirect costs are presented in Table 3. The
sum of net sick leave and net disability pension days in the
history of major CVD cohort increased by 4.35 in cases and
decreased by 10.70 in controls between the pre and post
periods. The DiD estimate of total days lost due to the
event during the 1st year after the event was thus 15.05,
corresponding to indirect costs of 2210 EUR. In the CHD
risk equivalent cohort, cases experienced an increase of
9.67 days lost between the two periods. Controls experi-
enced a decrease of 12.11 days during the same period,
yielding a DiD estimate of days lost due to the event during
the year after the event of 21.78. This corresponded to
indirect costs of 3119 EUR.
Productivity loss by type of event
Productivity loss and associated indirect costs were also
estimated by CV event type. These analyses were per-
formed for both strata combined. Figure 2 presents DiD
estimates of productivity loss and associated indirect costs
by index CV event type. MI was the most common event
(n = 966), followed by revascularization (n = 817),
ischemic stroke (n = 688), UA (n = 534), HF (n = 478),
and TIA (n = 214). The effect on productivity losses
varied substantially among these event types. The largest
impact was observed in patients experiencing ischemic
stroke (47 days; 6784 EUR). MI and UA also lead to sig-
nificant increases in productivity loss during the year fol-
lowing the event (25 and 17 days, corresponding to indirect
costs of 3465 EUR and 2733 EUR, respectively). The
Table 1 Patient baseline characteristics at index date for cases (matched patients with new cardiovascular events) and controls (matched patients
without new cardiovascular events), for both cohorts. CVD Cardiovacular disease, MI myocardial infarction
Patient baseline characteristics History of major CVD cohort (n = 4508) CHD risk equivalent cohort (n = 2946)
Cases (n = 2254) Controls (n = 2254) Cases (n = 1473) Controls (n = 1473)
Age [mean (SD)] 56.49 (5.95) 56.40 (5.86) 56.88 (5.89) 56.88 (5.93)
Female (%) 24 22 32 31
Charlson comorbidity index [mean (SD)] 2.00 (1.95) 1.46 (1.74) 2.27 (2.15) 1.77 (1.88)
Myocardial infarction (%) 36 24 2a 0
Diabetes mellitus (%) 24 18 49 45
Cerebrovascular disease (%) 22 20 11 6
Congestive heart failure (%) 18 7 14 5
Chronic pulmonary disease (%) 10 7 13 8
Peripheral vascular disease (%) 9 7 12 7
Moderate severe renal disease (%) 7 4 10 6
Malignancy (%) 6 6 6 7
Connective tissue disease (%) 4 3 4 3
Ulcer disease (%) 3 2 3 2
a Patients with no primary diagnosis of MI prior to study inclusion but who had an MI listed as a secondary diagnosis between study inclusion
and index event
Table 2 Productivity losses in
cases and controls, both cohorts
n Mean days of sick leave ? disability pension (SE)
Pre-period Post-period Difference
History of major CVD cohort
Cases 2254 154.35 (3.38) 158.70 (3.46) 4.35
Controls 2254 119.94 (3.28) 109.24 (3.64) -10.70
Difference 15.05*
CHD risk equivalent cohort
Cases 1473 149.81 (4.25) 159.48 (4.40) 9.67
Controls 1473 107.10 (3.93) 94.99 (4.25) -12.11
Difference 21.78*
* P\ 0.01
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effects of revascularization, TIA, and HF were statistically
insignificant.
Discussion
The objective of this study was to estimate productivity
loss and indirect costs associated with CV events in high-
risk hyperlipidemia patients in Sweden. Estimates were
generated for two distinct CV risk levels, as well as by type
of event. There is a scarcity of available data on produc-
tivity losses and related indirect costs specifically due to
CV events. Further, there is a lack of understanding of the
effects of CV events across the continuum of patients at
elevated risk of experiencing such events and of how these
effects may vary depending on the type of event. Zethraeus
et al. [11] estimated the direct and indirect costs of CHD
and stroke in Sweden and presented estimates by type of
clinical event. However, the study is relatively old and is
limited by its sample size (n = 12 for each event type in
the calculations of indirect costs). In addition, indirect costs
were calculated by multiplying the number of weeks that
the individual worked during a year by the mean number of
hours of work per week and the labor costs for wage
earners in mining and manufacturing. This differs from the
human capital approach used to calculate indirect costs in
this study. Lindgren et al. [12] similarly estimated indirect
costs associated with cardiovascular events. However, the
Lindgren study was also limited by sample size (n = 60)
and estimated productivity losses and resulting indirect
costs through the use of a questionnaire. The estimates are
thus vulnerable to recall bias. Further, estimates of indirect
costs were not presented by type of event. A recent study
by Song et al. [15] addresses many of these issues by
providing up-to-date estimates of indirect costs by event
type using a large sample of patients with hyperlipidemia.
The study controlled for confounders by matching patients
with and without events using propensity score matching.
However, differences in unobservable characteristics
between cases and controls were not controlled for. In
contrast, the DiD approach used in this study controls for
all time-invariant observable and unobservable
characteristics.
The stratification of patients by risk level and by type of
event contributes to filling important evidence gaps in the
literature and is an important strength of this study. The
high representativeness and the quality of the data used in
the analyses are also strengths. Sweden is well-known for
having excellent registers with a high degree of validity
and completeness that allow for generating real-world
Table 3 Indirect costs of cases
and controls, both cohorts
n Mean cost of sick leave ? disability pension in EUR (SE)
Pre-period Post-period Difference
History of major CVD cohort
Cases 2254 21,994 (483.29) 22,667 (496.70) 673
Controls 2254 17,135 (470.10) 15,598 (521.40) -1537
Difference 2210*
CHD risk equivalent cohort
Cases 1473 21,023 (598.16) 22,460 (617.51) 1437
Controls 1473 14,993 (551.87) 13,311 (600.38) -1682
Difference 3119*
* P value\0.01
Fig. 2 Difference-in-differences (DiD) estimate of productivity loss
and indirect costs by index cardiovascular (CV) event type (both
cohorts combined). MI Myocardial infarction, UA unstable angina,
PTCA percutaneous transluminal coronary angioplasty (revascular-
ization), IS ischemic stroke, TIA transient ischemic attack, HF heart
failure
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evidence of high quality. Furthermore, a unique feature of
this study is that estimates of the impact of CV events on
productivity loss were generated by a DiD approach. The
DiD approach controls for time-invariant observable and
unobservable factors, as well as secular trends and shocks
in the outcome variables over time that are common to
cases and controls. Matching on observable characteristics
was performed in order to ensure that trends and shocks in
the outcome variables were common to cases and controls.
The estimates should be viewed as conservative, as the
analysis does not include short-term sick leave episodes
and patients were censored at time of a second event fol-
lowing index event.
A limitation of the study is the lack of a natural index
date for controls, as controls by design did not experience
any events during exposure time. Cases and controls were
therefore matched based on their characteristics at study
inclusion rather than at start of follow-up (i.e. index date),
when the comparison of cases and controls starts. Controls
were then assigned the same index date as that of their
matched cases. This discrepancy may have led to matched
pairs being less comparable at start of follow-up than they
were at the time of matching. There was some evidence of
this, as cases had a higher Charlson comorbidity index at
index date compared to their matched controls and baseline
productivity losses of cases were generally higher than in
controls.
It should also be noted that not all data on productivity
loss were available for analysis. Short-term sick leave
episodes (B14 days) are the responsibility of the employer
in Sweden and are therefore not recorded in the Social
Insurance Register. Thus, such episodes could not be
included in the analysis. The first 14 days of all recorded
sick leave episodes (i.e., those longer than 14 days) are
recorded in the register, however. Even so, the study
underestimates total productivity losses and associated
costs of CV events due to this limitation. The finding that
revascularization did not lead to an increase in productivity
loss is likely due to the fact that short-term sick leave
episodes are not captured in the study. Revascularization
differs from the other events in that it is a procedure rather
than a medical condition. Revascularizations can therefore
be planned, meaning that the sick leave following the
procedure can also be planned. Sick leave episodes fol-
lowing planned revascularizations are therefore often
shorter than the 15 days required for the episode to be
recorded in the Social Insurance Register. Caution is thus
warranted when interpreting the estimates of the effect of
revascularization.
Further, the observation time of patients was shorter
during the period following index event compared to the
pre-period used as a baseline, due to patients dying during
the period following index event as well as being censored
at time of a second event. This in turn results in produc-
tivity losses being lower during the post-index periods than
they otherwise would have been, as patients will by defi-
nition experience no productivity losses once they are
deceased or censored. In addition, since pre-index levels of
productivity losses were higher in cases than in controls,
this decrease was greater in cases than in controls in
absolute terms. This further impacts the DiD estimates
obtained, in the case of TIA even leading to a negative
estimate (i.e. indicating that a TIA is associated with cost
savings). At the same time, cross-sectional comparisons of
cases and controls would be insufficient, due to the fact that
pre-index levels of productivity losses were higher in cases
than in controls. Similarly, within-subject comparisons do
not control for changes in the outcome variable that would
have occurred even in the absence of an event.
In conclusion, this study demonstrates that CV events in
Sweden are associated with substantial short-term pro-
ductivity losses and consequent indirect costs in high-risk
working-age patients treated for hyperlipidemia, high-
lighting the unmet needs of these patients. Large produc-
tivity losses prior to index event were also demonstrated, as
patients had between 107 and 154 mean days lost during
the year prior to index event. This burden significantly
impacts employers and society as a whole. There is thus
large potential for reducing productivity loss and associ-
ated costs from new interventions that would help in pri-
mary and secondary prevention of CV events. However,
the effect on productivity losses varies considerably
depending on the type of event, with ischemic stroke
associated with by far the largest indirect costs of the
investigated event types.
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